Physician profile
Christopher B Simkins
NPI 1992977854
$8,133.86
in general payments reported to CMS, 2019-2025
20 companies · $3,076 in 2025
The $3,076 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $1,765 · 2023: $1,429 · 2024: $1,513 · 2025: $3,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,908 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,908.36 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,607.97 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,542.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $871.65 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $775.24 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $641.92 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $609.30 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $597.63 | 2022-2025 | Austedo, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $473.96 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $273.35 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $227.62 | 2021-2025 | Spravato, Invega, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $200.15 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $152.09 | 2022-2025 | Rexulti |
| Sage Therapeutics, LLC | $46.46 | 2024 | |
| Almatica Pharma LLC | $22.20 | 2023 | Gralise |
| Lilly USA, LLC | $19.84 | 2025 | Mounjaro, Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $16.89 | 2021 | |
| Merck Sharp & Dohme LLC | $16.34 | 2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $14.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.02 | 2022 | |
| Noven Therapeutics, LLC | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Simkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.